Re:Gilead Shot Prevents All HIV Cases in Trial of African Women
by ffgjgf1 on Friday June 21, 2024 @08:27AM
(#40748880)
> In countries with public health care, setting the price that high will typically result in near-zero sales,
I’m not sure that’s strictly true at least when it comes to the most expensive/newly developed drugs:
https://www.investigate-europe.eu/posts/deadly-prices-medici...
Doesn’t seem that massively different from the relationship between insurance companies and drug companies in the US.
> In countries with public health care, setting the price that high will typically result in near-zero sales
Interestingly enough it seems like the poorer Central/East European countries end up paying more than the richer ones.
It doesn't always work like this. Some drugs are just too expensive to manufacture and the minimum profitable price is too high for the benefit in public health care. But often the bargaining and purchasing power of a public health care system can achieve lower prices for drugs and other tools.